What is PathAI?
Headquartered in Boston, Massachusetts, PathAI operates at the intersection of advanced machine learning and clinical pathology. The company provides a sophisticated suite of AI-powered research tools and services designed to assist pathologists in identifying disease markers with greater precision. By integrating deep learning algorithms into the diagnostic process, PathAI aims to reduce variability in results and improve patient outcomes for critical conditions such as cancer. The company's market position is bolstered by its ability to bridge the gap between raw biological data and actionable clinical insights, making it an essential partner for biopharmaceutical companies and healthcare providers focused on the next generation of precision medicine.
How much funding has PathAI raised?
PathAI has raised a total of $180.2M across 3 funding rounds:
Other Financing Round
$4.2M
Series A
$11M
Series C
$165M
Other Financing Round (2016): $4.2M with participation from Refactor Capital, 8VC, Pillar VC, and Fairhaven Capital
Series A (2017): $11M led by Pillar VC, Danhua Capital, 8VC, KdT Ventures, General Catalyst, and Refactor Capital
Series C (2021): $165M supported by KdT Ventures, General Atlantic, Polaris Partners, Merck Global Health Innovation Fund, 8VC, Adage Technologies, Kaiser Permanente, Bristol-Myers Squibb, Refactor Capital, Tiger Global Management, Biospring Partners, D1 Capital Partners, General Catalyst, and Labcorp
Key Investors in PathAI
General Catalyst
General Catalyst is a venture capital firm that partners with founders to build enduring enterprises, providing strategic capital and operational support to companies at critical inflection points.
Pillar VC
Pillar VC is a Boston-based firm specializing in early-stage and seed funding, dedicated to supporting entrepreneurs from the inception of their ideas through to real-world application.
Refactor Capital
Refactor Capital is an early-stage venture capital firm that focuses on investing in hard tech founders who are addressing fundamental human problems through innovative technology.
What's next for PathAI?
Following this major strategic investment, PathAI is well-positioned to expand its operational footprint and deepen its integration within the global biopharmaceutical ecosystem. The company is expected to prioritize the scaling of its diagnostic platform, focusing on the development of new AI models that address unmet needs in therapeutic research and clinical trial optimization. As the healthcare industry increasingly shifts toward data-driven decision-making, PathAI's focus on high-fidelity pathology services will likely serve as a cornerstone for future advancements in personalized treatment protocols. The firm's ability to maintain strong relationships with institutional investors and strategic partners suggests a clear path toward long-term market leadership in the health-tech sector.
See full PathAI company page
